|
KMID : 1140920220460040163
|
|
Annals of Rehabilitation Medicine
2022 Volume.46 No. 4 p.163 ~ p.171
|
|
|
Efficacy and Safety of Botulinum Toxin Type A (NABOTA) for Post-stroke Upper Extremity Spasticity: A Multicenter Phase IV Trial
|
|
Hwang Won-Jae
Kang Seong-Min
Lee Sang-Yoon
Seo Han-Gil
Park Yoon-Ghil
Kwon Bum-Sun
Lee Kwang-Jae
Kim Deog-Young
Kim Hyoung-Seop
Lee Shi-Uk
|
|
|
Abstract
|
|
|
Objective: To evaluate the efficacy and safety of Daewoong botulinum toxin type A (NABOTA) after its launch in South Korea.
Methods: This prospective, multicenter, open-label phase IV clinical trial included 222 patients with stroke. All patients visited the clinic at baseline and at weeks 4, 8, and 12 after injection of upto 360 units of NABOTA into the wrist, elbow, and finger flexor muscles at the first visit. The primary outcome was the change in Modified Ashworth Scale (MAS) score for the wrist flexor muscles between baseline and week 4. The secondary outcomes were the changes in MAS, Disability Assessment Scale (DAS), and Caregiver Burden Scale (CBS) scores between baseline and each visit, and the Global Assessment Scale (GAS) score at week 12.
Results: There was a statistically significant decrease in the MAS score for the wrist flexors between baseline and week 4 (?0.97±0.66, p<0.001). Compared with baseline, the MAS, DAS and CBS scores improved significantly during the study period. The GAS was rated as very good or good by 86.8% of physicians and by 60.0% of patients (or caregivers). The incidence of adverse events was 14.4%, which is smaller than that in a previous trial.
Conclusion: NABOTA showed considerable efficacy and safety in the management of upper limb spasticity in stroke patients.
|
|
|
KEYWORD
|
|
|
Stroke, Muscle spasticity, Botulinum toxin type A, Treatment efficacy, Safety, Clinical trial, Phase 4
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|